ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

19 12 2024 07:30:00 提供 Nasdaq GlobeNewswire

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

16 12 2024 07:30:00 提供 Nasdaq GlobeNewswire

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

12 12 2024 15:01:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma Reports Third Quarter 2024 Financial Results

14 11 2024 15:01:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

07 11 2024 15:01:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

04 11 2024 06:00:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

30 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

30 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

19 9 2024 19:16:32 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

18 9 2024 15:04:11 提供 Nasdaq GlobeNewswire

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

16 9 2024 06:00:00 提供 Nasdaq GlobeNewswire

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

13 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

11 9 2024 16:37:50 提供 Nasdaq GlobeNewswire

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

03 9 2024 16:06:29 提供 Nasdaq GlobeNewswire

Ascendis Pharma Reports Second Quarter 2024 Financial Results

03 9 2024 16:04:32 提供 Nasdaq GlobeNewswire

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

28 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults

12 8 2024 06:00:00 提供 Nasdaq GlobeNewswire

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

24 6 2024 15:45:36 提供 Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

04 6 2024 15:01:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

03 6 2024 15:01:00 提供 Nasdaq GlobeNewswire